Suppr超能文献

用于部分有序药物组合的半参数剂量寻找方法。

SEMIPARAMETRIC DOSE FINDING METHODS FOR PARTIALLY ORDERED DRUG COMBINATIONS.

作者信息

Clertant Matthieu, Wages Nolan A, O'Quigley John

机构信息

LAGA, LabEx Inflamex, Université Sorbonne Paris Nord, France.

Translational Research and Applied Statistics, University of Virginia, U.S.A.

出版信息

Stat Sin. 2022;32:1983-2005. doi: 10.5705/ss.202020.0248.

Abstract

We investigate a statistical framework for Phase I clinical trials that test the safety of two or more agents in combination. For such studies, the traditional assumption of a simple monotonic relation between dose and the probability of an adverse event no longer holds. Nonetheless, the dose toxicity (adverse event) relationship will obey an assumption of partial ordering in that there will be pairs of combinations for which the ordering of the toxicity probabilities is known. Some authors have considered how to best estimate the maximum tolerated dose (a dose providing a rate of toxicity as close as possible to some target rate) in this setting. A related, and equally interesting, problem is to partition the 2-dimensional dose space into two sub-regions: doses with probabilities of toxicity lower and greater than the target. We carry out a detailed investigation of this problem. The theoretical framework for this is the recently presented semiparametric dose finding method. This results in a number of proposals one of which can be viewed as an extension of the Product of Independent beta Priors Escalation method (PIPE). We derive useful asymptotic properties which also apply to the PIPE method when seen as a special case of the more general method given here. Simulation studies provide added confidence concerning the good behaviour of the operating characteristics.

摘要

我们研究了一种用于I期临床试验的统计框架,该试验用于测试两种或更多药物联合使用时的安全性。对于此类研究,剂量与不良事件概率之间存在简单单调关系的传统假设不再成立。尽管如此,剂量毒性(不良事件)关系将遵循部分排序的假设,即存在毒性概率排序已知的组合对。一些作者已经考虑了在这种情况下如何最好地估计最大耐受剂量(一种毒性发生率尽可能接近某个目标发生率的剂量)。一个相关且同样有趣的问题是将二维剂量空间划分为两个子区域:毒性概率低于和高于目标的剂量区域。我们对这个问题进行了详细研究。其理论框架是最近提出的半参数剂量寻找方法。这产生了许多提议,其中之一可以被视为独立贝塔先验递增乘积方法(PIPE)的扩展。我们推导出了有用的渐近性质,当将PIPE方法视为此处给出的更一般方法的特殊情况时,这些性质也适用于PIPE方法。模拟研究为操作特性的良好表现提供了更多信心。

相似文献

1
SEMIPARAMETRIC DOSE FINDING METHODS FOR PARTIALLY ORDERED DRUG COMBINATIONS.
Stat Sin. 2022;32:1983-2005. doi: 10.5705/ss.202020.0248.
2
A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
Clin Trials. 2020 Oct;17(5):522-534. doi: 10.1177/1740774520932130. Epub 2020 Jul 7.
3
Dose-finding design for multi-drug combinations.
Clin Trials. 2011 Aug;8(4):380-9. doi: 10.1177/1740774511408748. Epub 2011 Jun 7.
4
A nonparametric Bayesian method for dose finding in drug combinations cancer trials.
Stat Med. 2022 Mar 15;41(6):1059-1080. doi: 10.1002/sim.9316. Epub 2022 Jan 25.
6
Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
Stat Med. 2015 Feb 28;34(5):859-75. doi: 10.1002/sim.6376. Epub 2014 Nov 21.
7
Continual reassessment method for partial ordering.
Biometrics. 2011 Dec;67(4):1555-63. doi: 10.1111/j.1541-0420.2011.01560.x. Epub 2011 Mar 1.
8
Using the time-to-event continual reassessment method in the presence of partial orders.
Stat Med. 2013 Jan 15;32(1):131-41. doi: 10.1002/sim.5491. Epub 2012 Jul 17.
10
Dynamic ordering design for dose finding in drug-combination trials.
Pharm Stat. 2021 Mar;20(2):348-361. doi: 10.1002/pst.2081. Epub 2020 Nov 24.

引用本文的文献

1
Comb-BOIN12: A Utility-Based Bayesian Optimal Interval Design for Dose Optimization in Cancer Drug-Combination Trials.
Stat Biopharm Res. 2025;17(2):266-276. doi: 10.1080/19466315.2024.2370403. Epub 2024 Aug 28.
2
3
Applications of the partial-order continual reassessment method in the early development of treatment combinations.
Clin Trials. 2024 Jun;21(3):331-339. doi: 10.1177/17407745241234634. Epub 2024 Mar 30.
4
Local continual reassessment methods for dose finding and optimization in drug-combination trials.
Stat Methods Med Res. 2023 Oct;32(10):2049-2063. doi: 10.1177/09622802231192955. Epub 2023 Aug 18.
5
CUSUMIN: A cumulative sum interval design for cancer phase I dose finding studies.
Pharm Stat. 2022 Nov;21(6):1324-1341. doi: 10.1002/pst.2247. Epub 2022 Jul 14.
6
A nonparametric Bayesian method for dose finding in drug combinations cancer trials.
Stat Med. 2022 Mar 15;41(6):1059-1080. doi: 10.1002/sim.9316. Epub 2022 Jan 25.
7
Fractional design: An alternative paradigm for late-onset toxicities in oncology dose-finding studies.
Contemp Clin Trials Commun. 2020 Aug 18;19:100650. doi: 10.1016/j.conctc.2020.100650. eCollection 2020 Sep.
8
Evaluation of irrational dose assignment definitions using the continual reassessment method.
Clin Trials. 2019 Dec;16(6):665-672. doi: 10.1177/1740774519873316. Epub 2019 Sep 23.

本文引用的文献

1
Dose expansion cohorts in Phase I trials.
Stat Biopharm Res. 2016;8(2):161-170. doi: 10.1080/19466315.2015.1135185. Epub 2016 Jun 2.
2
A product of independent beta probabilities dose escalation design for dual-agent phase I trials.
Stat Med. 2015 Apr 15;34(8):1261-76. doi: 10.1002/sim.6434. Epub 2015 Jan 29.
3
Best Invariant and Minimax Estimation of Quantiles in Finite Populations.
J Stat Plan Inference. 2011 Aug 1;141(8):2633-2644. doi: 10.1016/j.jspi.2011.02.016.
4
Continual reassessment method for partial ordering.
Biometrics. 2011 Dec;67(4):1555-63. doi: 10.1111/j.1541-0420.2011.01560.x. Epub 2011 Mar 1.
5
A modified toxicity probability interval method for dose-finding trials.
Clin Trials. 2010 Dec;7(6):653-63. doi: 10.1177/1740774510382799. Epub 2010 Oct 8.
6
A hierarchical Bayesian design for phase I trials of novel combinations of cancer therapeutic agents.
Biometrics. 2010 Sep;66(3):805-12. doi: 10.1111/j.1541-0420.2009.01363.x.
7
A parallel phase I/II clinical trial design for combination therapies.
Biometrics. 2007 Jun;63(2):429-36. doi: 10.1111/j.1541-0420.2006.00685.x.
8
Two-dimensional dose finding in discrete dose space.
Biometrics. 2005 Mar;61(1):217-22. doi: 10.1111/j.0006-341X.2005.030540.x.
9
Dose-finding with two agents in Phase I oncology trials.
Biometrics. 2003 Sep;59(3):487-96. doi: 10.1111/1541-0420.00058.
10
Design and analysis of phase I clinical trials.
Biometrics. 1989 Sep;45(3):925-37.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验